These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22912565)

  • 1. Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions.
    Duke JD; Han X; Wang Z; Subhadarshini A; Karnik SD; Li X; Hall SD; Jin Y; Callaghan JT; Overhage MJ; Flockhart DA; Strother RM; Quinney SK; Li L
    PLoS Comput Biol; 2012; 8(8):e1002614. PubMed ID: 22912565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Mechanistic Investigation of Drug-Drug Interactions Associated With Myopathy: A Translational Approach.
    Han X; Quinney SK; Wang Z; Zhang P; Duke J; Desta Z; Elmendorf JS; Flockhart DA; Li L
    Clin Pharmacol Ther; 2015 Sep; 98(3):321-7. PubMed ID: 25975815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational High-Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models.
    Chiang CW; Zhang P; Wang X; Wang L; Zhang S; Ning X; Shen L; Quinney SK; Li L
    Clin Pharmacol Ther; 2018 Feb; 103(2):287-295. PubMed ID: 29052226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixture drug-count response model for the high-dimensional drug combinatory effect on myopathy.
    Wang X; Zhang P; Chiang CW; Wu H; Shen L; Ning X; Zeng D; Wang L; Quinney SK; Feng W; Li L
    Stat Med; 2018 Feb; 37(4):673-686. PubMed ID: 29171062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.
    Lu C; Miwa GT; Prakash SR; Gan LS; Balani SK
    Drug Metab Dispos; 2007 Jan; 35(1):79-85. PubMed ID: 17020957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive-Unlabeled Learning for inferring drug interactions based on heterogeneous attributes.
    Hameed PN; Verspoor K; Kusljic S; Halgamuge S
    BMC Bioinformatics; 2017 Mar; 18(1):140. PubMed ID: 28249566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
    Lu C; Hatsis P; Berg C; Lee FW; Balani SK
    Drug Metab Dispos; 2008 Jul; 36(7):1255-60. PubMed ID: 18381489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition.
    Hu M; Mak VW; Tomlinson B
    J Clin Pharm Ther; 2011 Jun; 36(3):419-25. PubMed ID: 21545622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data-driven prediction of adverse drug reactions induced by drug-drug interactions.
    Liu R; AbdulHameed MDM; Kumar K; Yu X; Wallqvist A; Reifman J
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):44. PubMed ID: 28595649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mining and visualizing high-order directional drug interaction effects using the FAERS database.
    Yao X; Tsang T; Sun Q; Quinney S; Zhang P; Ning X; Li L; Shen L
    BMC Med Inform Decis Mak; 2020 Mar; 20(Suppl 2):50. PubMed ID: 32183790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine.
    Johnston SS; Udall M; Cappelleri JC; Johnson BH; Shrady G; Chu BC; Silverman SL
    Am J Health Syst Pharm; 2013 Dec; 70(24):2207-17. PubMed ID: 24296843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 Isoforms.
    Dmitriev AV; Rudik AV; Karasev DA; Pogodin PV; Lagunin AA; Filimonov DA; Poroikov VV
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33924315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DDIWAS: High-throughput electronic health record-based screening of drug-drug interactions.
    Wu P; Nelson SD; Zhao J; Stone CA; Feng Q; Chen Q; Larson EA; Li B; Cox NJ; Stein CM; Phillips EJ; Roden DM; Denny JC; Wei WQ
    J Am Med Inform Assoc; 2021 Jul; 28(7):1421-1430. PubMed ID: 33712848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes.
    Preskorn SH
    J Psychiatr Pract; 2020 Mar; 26(2):126-134. PubMed ID: 32134885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
    Molden E; Skovlund E; Braathen P
    Drug Saf; 2008; 31(7):587-96. PubMed ID: 18558792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.
    Ohno Y; Hisaka A; Ueno M; Suzuki H
    Clin Pharmacokinet; 2008; 47(10):669-80. PubMed ID: 18783297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
    Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
    Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential clinically significant drug-drug interactions of hydroxychloroquine used in the treatment of COVID-19.
    Biswas M; Roy DN
    Int J Clin Pract; 2021 Nov; 75(11):e14710. PubMed ID: 34370370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.
    Gruer PJ; Vega JM; Mercuri MF; Dobrinska MR; Tobert JA
    Am J Cardiol; 1999 Oct; 84(7):811-5. PubMed ID: 10513779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.